Bristol-Myers Squibb (BMY) Tops Q2 EPS by 40c; raises guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $58.56 +1.81%
EPS Growth %: +10.3%
Financial Fact:
Provision for income taxes: 344M
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: +10.3%
Financial Fact:
Provision for income taxes: 344M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.46, $0.40 better than the analyst estimate of $1.06. Revenue for the quarter came in at $12.27 billion versus the consensus estimate of $11.34 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2025 EPS of $6.35-$6.65, versus the consensus of $6.32. Bristol-Myers Squibb sees FY2025 revenue of $46.5-47.5 billion, versus the consensus of $46.265 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Jones Trading Starts Alterity Therapeutics (ATHE) at Buy
- W. P. Carey prices $350 million in senior notes due 2036
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
